Modulation of Autism-Associated Serotonin Transporters by Palmitoylation: Insights into the Molecular Pathogenesis and Targeted Therapies for Autism Spectrum Disorder.

Scientists studied how a protein that moves serotonin (a brain chemical) works differently in some people with autism. They found that certain genetic changes make this protein work too hard, which might contribute to autism symptoms. The antidepressant escitalopram was able to bring the protein's activity back to normal levels, helping explain why this medication might help some autism symptoms.

This molecular study investigated serotonin transporter (SERT) modifications in autism spectrum disorder (ASD). Researchers examined two rare SERT genetic variants (F465L and L550V) found in ASD patients, focusing on a cellular process called palmitoylation that affects protein function. The study found that these ASD-associated variants showed enhanced palmitoylation, increased surface expression, and elevated serotonin transport capacity compared to normal SERT. Treatment with escitalopram (an SSRI antidepressant) or 2-bromopalmitate restored these abnormal characteristics to normal levels.

The findings suggest that abnormal SERT palmitoylation may contribute to ASD pathogenesis and provide molecular insights into why escitalopram may be therapeutically beneficial for some ASD symptoms.

Findings suggest potential for personalized autism treatment approaches targeting SERT function, particularly for individuals with specific genetic variants. May inform precision medicine strategies and explain variable responses to SSRI medications in autism.

This appears to be a laboratory-based molecular study with unclear sample sizes and methodology details. Clinical translation and relevance to broader autism population remains uncertain without human subject data.

Autism spectrum disorder (ASD) is a developmental disorder of the nervous system characterized by a deficiency in interpersonal communication skills, a pathologic tendency for repetitive behaviors, and highly restrictive interests. The spectrum is a gradient-based construct used to categorize the widely varying degrees of ASD phenotypes, and has been linked to a genetic etiology in 25% of cases. Prior studies have revealed that 30% of ASD patients exhibit hyperserotonemia, or severely elevated whole blood serotonin (5HT), implicating the serotonergic system in the pathogenesis of ASD. Likewise, escitalopram, a selective-serotonin reuptake inhibitor (SSRI), has been demonstrated to effectively improve core ASD symptoms potentially by modulating abnormal brain activation in ASD patients.

Molecular studies have uncovered proband patients with rare mutations in the serotonin transporter (SERT) that manifest enhanced surface expression and 5HT transport capacity, suggesting that abnormal enhancement of SERT function may be involved in the pathogenesis of ASD. Here, we reveal that palmitoylation is enhanced in the ASD SERT F465L and L550V coding variants, and confirm prior reports of enhanced kinetic activity and surface expression of F465L. Furthermore, treatment of F465L with the irreversible palmitoyl acyl-transferase inhibitor, 2-bromopalmitate (2BP), or escitalopram, rectified enhanced F465L palmitoylation, surface expression, and transport capacity to basal WT levels. Overall, our results implicate disordered SERT palmitoylation in the pathogenic mechanism of ASD, with basal recovery of these processes following escitalopram treatment providing insight into its molecular utility as an ASD therapeutic.